Clinical trials: High Risk Localised Prostate Carcinoma
Prostate Adenocarcinoma
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free…
- Trial name
- NCT01985828
- Testing
- CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
The study is to examine a moderate hypofractionation regimen of proton beam therapy for high risk or unfavorable intermediate risk prostate cancer.
- Trial name
- NCT02874014
- Testing
- Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00033631
- Testing
- 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
- Where
- 86 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Radiation Therapy Oncology Group
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
- Trial name
- NCT00860158
- Testing
- Dasatinib, Leuprolide Acetate (LHRH Analogue), Radical Prostatectomy
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Noah Hahn, M.D.
Prostate Cancer
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical…
- Trial name
- NCT02923180
- Testing
- Enoblituzumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)
- Trial name
- NCT00828308
- Testing
- Ixabepilone, Prostatectomy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brown University
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.
- Trial name
- NCT00500110
- Testing
- Docetaxel, Imatinib Mesylate, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.
- Trial name
- NCT00116142
- Testing
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Dana-Farber Cancer Institute
High Risk Prostate Cancer
Neoadjuvant BKM120 in High-risk Prostate Cancer
This is a phase II, study of BKM120 in patients with high-risk, localized prostate cancer. Eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy of the prostate to confirm high-risk disease and…
- Trial name
- NCT01695473
- Testing
- BKM120
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Won Kim
Prostate Cancer
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.
- Trial name
- NCT01686958
- Testing
- MR-Guided Transurethral US Ablation of Prostate Tissue
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Profound Medical Inc.
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00466752
- Testing
- sorafenib tosylate, microarray analysis, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Prostate Cancer
The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
Silibinin has demonstrated anti-cancer activity in the laboratory for several different cancer types, including prostate cancer. Silibinin was originally obtained from milk thistle.
- Trial name
- NCT00487721
- Testing
- Silibin-Phytosome
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in…
- Trial name
- NCT00924469
- Testing
- Abiraterone, Leuprolide, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).
- Trial name
- NCT00577356
- Testing
- Docetaxel, CG1940/CG8711
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Benaroya Research Institute
Castrate Resistant Prostate Cancer
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
This multicenter Phase I/II trial consists of two stages: a phase I stage in patients with castration resistant prostate cancer in which the recommended phase II dose will be determined for ipatasertib administered in combination…
- Trial name
- ADDItion (NCT04737109)
- Testing
- Ipatasertib, Darolutamide, Androgen Deprivation Therapy
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- David VanderWeele
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center